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Abstract
Introduction: Mortality is the most widely accepted outcome measure in randomized controlled trials of therapies for 
critically ill adults, but most of these trials fail to show a statistically significant mortality benefit. The reasons for this are 
unknown.
Methods: We searched five high impact journals (Annals of Internal Medicine, British Medical Journal, JAMA, The 
Lancet, New England Journal of Medicine) for randomized controlled trials comparing mortality of therapies for 
critically ill adults over a ten year period. We abstracted data on the statistical design and results of these trials to 
compare the predicted delta (delta; the effect size of the therapy compared to control expressed as an absolute 
mortality reduction) to the observed delta to determine if there is a systematic overestimation of predicted delta that 
might explain the high prevalence of negative results in these trials.
Results: We found 38 trials meeting our inclusion criteria. Only 5/38 (13.2%) of the trials provided justification for the 
predicted delta. The mean predicted delta among the 38 trials was 10.1% and the mean observed delta was 1.4% (P < 
0.0001), resulting in a delta-gap of 8.7%. In only 2/38 (5.3%) of the trials did the observed delta exceed the predicted 
delta and only 7/38 (18.4%) of the trials demonstrated statistically significant results in the hypothesized direction; 
these trials had smaller delta-gaps than the remainder of the trials (delta-gap 0.9% versus 10.5%; P < 0.0001). For trials 
showing non-significant trends toward benefit greater than 3%, large increases in sample size (380% - 1100%) would 
be required if repeat trials use the observed delta from the index trial as the predicted delta for a follow-up study.
Conclusions: Investigators of therapies for critical illness systematically overestimate treatment effect size (delta) 
during the design of randomized controlled trials. This bias, which we refer to as "delta inflation", is a potential reason 
that these trials have a high rate of negative results.
“Absence of evidence is not evidence of absence.”
Introduction
Mortality has become the standard outcome measure in
trials of therapies in critically ill adults because it obviates
debate about clinical relevance and concerns of ascertain-
ment bias. However, it has recently been noted that the
majority of these trials fail to demonstrate efficacy [1] and
several therapies that appeared promising did not dem-
onstrate efficacy on repeated study [2-7]. The high rate of
negative results in these trials could be explained by sev-
eral possibilities including true lack of efficacy (the null
hypothesis is true), type II statistical errors in trials with
adequate power, and methodological problems in study
design leading to inadequate power and sample size [8].
Several parameters must be chosen by investigators in
the design of a trial of mortality in order to determine the
required sample size, including the significance level
required for rejection of the null hypothesis; power; the
predicted mortality rate in the placebo arm; and the pre-
dicted effect size (delta). In contrast to significance level
and power, which are usually set by convention at 0.05
and 90%, respectively, predictions about the placebo mor-
tality rate must be guided by preliminary data (if avail-
able) or guesswork. Likewise, predictions of delta are
either based on existing data or are guided by biological
plausibility or a minimal clinically important difference
(MCID) [9,10]. Using these four variables (significance
level, power, baseline mortality rate, and delta) sample
size required for the trial can be calculated.
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Unfortunately, sample size is often not determined in
this fashion [11-13]. As a result of financial, time, and
logistical constraints [14], investigators often first esti-
mate the number of patients that they can expect to
enroll during the planned duration of the trial with avail-
able resources. Then, using conventional values for sig-
nificance level and power, they calculate the delta that
they can expect to find using that sample size, in effect
performing sample size calculations in reverse. (It is also
not unusual for investigators to revise delta upward mid-
trial when declining enrollment is noted [15,16].) As a
result of this, values of predicted delta used by investiga-
tors in study design may not represent a realistic estimate
of the effect of a therapy on outcomes. As shown in Table
1, sample size determinations are much more sensitive to
changes in delta than the other three variables; this fact,
combined with inflexibility with regard to significance
level and power (due to convention), may make delta
more susceptible to misuse and manipulation. We refer to
biased overestimates of effect size during trial design as
'delta inflation'. If it exists, delta inflation may result in
trials that have inadequate sample size to find true differ-
ences between a therapy and placebo, leading to a high
rate of falsely negative trials, with many attendant impli-
cations for critical care research and practice.
Materials and methods
One author (SKA) performed a search of the tables of
contents of five high-impact medical journals (BMJ, New
England Journal of Medicine,  Journal of the American
Medical Association, Lancet, Annals of Internal Medicine)
for titles containing the keywords (and variations
thereof) critically ill, intensive care, ICU, acute respira-
tory distress syndrome, acute lung injury, sepsis, shock,
ventilator, ventilation, respiratory failure, multiple organ
dysfunction, continuous veno-venous hemodialysis, and
renal failure, but not containing keywords related to pedi-
atrics (neonatal, infant, children, prematurity) published
between 1 January, 1999 and 22 July, 2009. Articles con-
taining included keywords were then reviewed further to
determine if they met inclusion and exclusion criteria.
Articles were included if they described a randomized
controlled trial in a critically ill adult population that
evaluated proportional mortality (mortality expressed as
a proportion as opposed to that measured as a mean sur-
vival or a time to event analysis) as the primary endpoint
upon which power calculations were based. Articles were
excluded if they described a non-inferiority trial, if they
dealt with a non-ICU population (out of hospital, pre-
hospital, or care not described as delivered in an ICU set-
ting), and if they included non-adult patients. Factorial
trials testing more than one therapy were considered as
separate trials for each therapy tested, even if reported in
the same manuscript.
Data were abstracted from articles meeting these crite-
ria utilizing a standardized form. We recorded variables
pertaining to statistical methods including significance
level, power, delta, the expected baseline (placebo or
standard care) mortality rate, the a priori sample size,
whether the study was terminated early, and any modifi-
cations made to the sample size in the middle of the trial.
We recorded whether the predicted delta was justified by
reference to either published or unpublished data. We
abstracted data from the results of the trial including the
number of patients in the treatment and placebo arms
that were included in the final data analysis, and the mor-
tality rate in each arm. W e recorded unadjusted results
and those pertaining to the overall (intention-to-treat)
population (so that the results would correspond to the
assumptions of the power calculations) even where the
authors emphasized adjusted or subgroup analyses. For
three trials that did not report the predicted delta, we
contacted the authors to obtain this information. For one
of these trials [17], the predicted delta could not be deter-
mined and the study was excluded. For the other two tri-
als, the authors provided information about the predicted
Table 1: Simulated scenarios for sample size determination in the design of a hypothetical study
Standard 
Scenario
Relaxed 
significance 
level
Relaxed Power Baseline 
Mortality shifted 
away from 50%
Inflated delta
Significance level 
(two-sided)
0.05 0.1 0.05 0.05 0.05
Power 90% 90% 80% 90% 90%
Baseline (placebo) 
mortality rate
50% 50% 50% 40% 50%
Delta (ARR) 10% 10% 10% 10% 15%
Required sample 
size
1076 884 816 992 480
Inflation of delta has a substantially larger impact on required sample size than changes in the other variables. ARR, absolute risk reduction.Aberegg et al. Critical Care 2010, 14:R77
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delta and sample size calculations not included in the
original manuscript.
Using these data, we performed confirmatory sample
size calculations for each trial, determined the observed
treatment effect (delta) and the difference between the
predicted and observed delta (the delta-gap), calculated
the 95% confidence interval for the observed delta, and
plotted a graph of observed versus predicted delta. We
calculated mean predicted and observed delta values
across all trials, and compared them using a paired t-test
with unequal variances. For non-statistically significant
trials that had an observed delta greater than the smallest
predicted delta of all the trials (3% [18]), we calculated the
sample size that would be required if the trials were to be
repeated using the observed delta of the index trial as the
predicted delta for the future trial. All statistical calcula-
tions were performed using STATA version 8.0 (College
Station, TX, USA).
Results
Our search identified 160 articles for further review. Of
these, 58 described trials that were not randomized con-
trolled trials, 46 were excluded because mortality was not
the primary outcome on which power calculations were
based, 12 were excluded because they dealt with non-
critically ill populations, 2 were excluded because they
described non-inferiority trials, 1 was excluded because it
dealt with pediatric patients, and 1 was excluded because
no predicted delta was reported and the authors could
not provide the information. The remaining 38 articles
were included in our analysis.
Additional file 1 shows the characteristics of the
included trials. Among all trials, only 5 of the 38 (13.2%)
provided justification for the predicted delta, and 7 of the
38 (18.4%) provided justification for the baseline mortal-
ity rate used in sample size calculations (data not shown).
Among all included trials, 27 of the 38 (71%) provided
sufficient information for us to replicate the sample size
calculations. For 20 of these 27 trials (74%), our sample
size calculations yielded values that deviated less than
10% from the a priori sample sizes specified in the manu-
script.
Figure 1 demonstrates graphically the main results of
our analysis comparing predicted and observed delta. As
seen in Figure 1, values for observed delta are not ran-
domly scattered around the blue line representing unity
with predicted delta, but rather fall almost uniformly
below it. Among all included trials, only 2 (5.3%) demon-
strated an observed delta equal to or greater than the pre-
dicted value [19,20]. The mean predicted delta among all
trials was 10.1%, the mean observed delta was 1.4% (P <
0.0001 for this comparison), and the mean difference
between predicted and observed delta (the delta-gap) was
8.7%. Among all trials, only 7 of the 38 included studies
(18.4%) demonstrated an unadjusted delta for the inten-
tion-to-treat population that was statistically significant
in the hypothesized direction (red triangles above zero on
the Y-axis in Figure 1). Among all trials, 26 of 38 (68.4%)
had 95% confidence intervals for observed delta that did
not include the predicted delta, in essence excluding an
effect of the therapy as great as the predicted delta. How-
ever, 31 of 38 (81.6%) of the trials had an associated 95%
confidence interval that included a delta of 3%, which was
the smallest predicted delta sought by investigators in all
of the trials [18].
Among all trials, 17 of 38 (44.7%) had an observed delta
with a negative value (that is, the treatment was numeri-
cally worse than the comparator). Three of these trials
showed a statistically significant increase in mortality
with the therapy, and all of these trials were stopped early
for harm [4,21,22]. The seven trials showing a statistically
significant difference favoring the therapy had a smaller
delta-gap compared with non-significant trials and those
demonstrating harm (delta-gap 0.9% versus 10.5%; P  <
0.0001). In Figure 1, these seven trials are represented by
red triangles above zero on the Y-axis; as can be seen
graphically, the deltas associated with these trials fall
closer to the blue unity line than the other trials.
For the eight trials that showed a non-statistically sig-
nificant point estimate for delta that exceeded the small-
est predicted delta of all trials (3% [18]), we calculated the
sample size that would be required to repeat the study
using the observed delta of the index study as the pre-
dicted delta for the repeat study. Repeating these trials in
this fashion would require increases in sample size from
380% to 1,100% compared with the sample size of the
index study (data not shown).
Discussion
We found that randomized controlled trials of therapies
in critical care medicine evaluating proportional mortal-
ity as a primary endpoint and published in five high-
impact medical journals during the past 10 years utilized
predicted values of delta in power calculations that sys-
tematically overestimated observed values of delta. We
propose that this phenomenon of 'delta inflation' repre-
sents a bias in the design of such trials with attendant
implications for the design of future trials and the prac-
tice of critical care medicine.
Our results accord with the findings of a recent report
that found low rates of efficacy in trials in critical care
medicine, a finding the authors attributed to the use of
m o r t a l i t y  a s  a n  e n d p o i n t  [ 1 ] .  W e  e x t e n d  t h i s  w o r k  b y
identifying a key feature of such trials, namely that the
predicted delta almost uniformly over-estimates the
observed delta. This phenomenon of 'delta inflation' is a
possible reason that many of these trials fail to demon-
strate efficacy. Other investigators have found discrepan-Aberegg et al. Critical Care 2010, 14:R77
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Figure 1 Plot of observed versus predicted delta (with associated 95% confidence intervals for observed delta) of 38 trials included in the 
analysis. Point estimates of treatment effect (deltas) are represented by green circles for non-statistically significant trials and red triangles for statis-
tically significant trials. Numbers within the circles and triangles refer to the trials as referenced in Additional file 1. The blue 'unity line' with a slope 
equal to one indicates perfect concordance between observed and predicted delta; for visual clarity and to reduce distortions, the slope is reduced 
to zero (and the x-axis is horizontally expanded) where multiple predicted deltas have the same value and where 95% confidence intervals cross the 
unity line. If predictions of delta were accurate and without bias, values of observed delta would be symmetrically scattered above and below the 
unity line. If there is directional bias, values will fall predominately on one side of the line as they do in the figure.Aberegg et al. Critical Care 2010, 14:R77
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cies between predicted and observed delta in other fields
and with other outcomes, but the overall prevalence of
delta inflation in clinical investigation is unknown
[23,24]. Our study also complements reports showing
that sample size calculations are inadequately or disin-
genuously reported in randomized controlled trials
[8,25,26]. It expands this work by demonstrating that
even when there is adequate reporting of statistical meth-
odology, one component of sample size estimation is
biased, thus rendering the entire procedure unreliable [9].
The reasons for the discrepancy between predicted and
observed delta cannot be determined from our data, but
beg speculation. One possibility is that investigators are
choosing delta based on sample size rather than choosing
sample size based on delta [8,11]. Another possibility is
that investigators are overly optimistic about the efficacy
and effect size of a therapy and that delta inflation is
borne of unrealistic optimism [27]. There may also be a
belief that effect sizes below some threshold (say, 10%)
are not clinically important, but this is a notion under-
mined by investigations that sought predicted delta val-
ues as low as 3% and by other evidence [18,28]. Moreover,
although it has been suggested that delta should be based
on an assessment of the MCID, our finding of wide varia-
tion in predicted deltas in studies with the same primary
outcome demonstrates that this is not happening [29-31].
Publication bias affecting pilot trials may cause those
with smaller effect sizes to go unpublished, thereby inflat-
ing the apparent benefit of a therapy when and if a litera-
ture search is performed [32]; however, the low rate of
referenced justification for predicted delta that we and
others have documented argues against this [24,33,34].
The insistence on mortality as the gold standard outcome
measure in critical care research combined with funding
constraints may pressure investigators to search for unre-
alistic mortality benefits and perhaps to hope that signifi-
cant improvements in secondary outcome measures will
lead to adoption of the therapy [35,36]. Indeed, the very
concept of power and the so-called 'double-significance'
approach to hypothesis testing and sample size determi-
nation has been called into question [37]. Finally, a loom-
ing possibility is that the null hypothesis is true and most
therapies for critical illness simply are not efficacious.
Given the wide confidence intervals around observed
delta in the trials in our analysis, this is impossible to dis-
prove with existing data. However, the consistent conduct
of trials of therapies that are in reality not efficacious
basically would consist of an extreme form of delta infla-
tion. In any case, investigators should take stock in the
fact that deltas of 10% or greater are rarely found, and
attention needs to be refocused on what is the minimal
clinically important difference in trials of therapies to
reduce mortality in critical illness [9,31].
Regardless of the causes of delta inflation, its effects are
likely deleterious. Firstly, some authors have argued that
underpowered trials are unethical and trials designed
with delta inflation are essentially underpowered [38].
Secondly, insomuch as delta inflation leads to trials that
are 'negative', it may contribute to the premature aban-
donment of promising therapies because of the com-
monly held belief that 'absence of evidence is evidence of
absence' [39]. This is compounded by the fact that delta
inflation can conceal the low statistical power of a trial,
thus falsely assuring clinicians that a true difference has
been ruled out by a trial with a low type II error rate.
Thirdly, the conduct of trials with delta inflation may rep-
resent a waste of resources because it undermines their
scientific and clinical validity and value to society.
If delta inflation exists, several approaches might mini-
mize its impact. Firstly, not only should predicted delta be
reported [40], but also should it be justified by a refer-
enced review of available evidence or a statement about
biological plausibility or the MCID, especially when pre-
dicted delta exceeds a nominal value such as 3% [18,24].
Results of trials should report confidence intervals for
delta rather than P values and should emphasize that the
results excluded a difference greater than the upper con-
fidence interval rather than stating that the results failed
to find a statistically significant difference [11,13,37]. A
'buffer' to account for delta inflation could be built into
power calculations as is now done for anticipated rates of
drop out and loss to follow up. Moreover, the use of mor-
tality as the only accepted primary outcome for trials of
therapies for critical illness should be reconsidered,
because few therapies in critical care are ultimately
shown to reduce mortality [1,23]. Consideration might be
given to the use of composite [41] or weighted composite
[42,43] endpoints in which each part of the composite is
weighted according to its relative value. For example, a
composite endpoint might be comprised of mortality,
renal replacement therapy, mechanical ventilation, non-
ambulatory status, or receiving nutritional support at
some pre-determined time point (e.g., 28 or 60 days).
More research related to long-term outcomes in critical
illness and their relative values will be needed to inform
the choice of components of composite endpoints [44].
There are several limitations of our study. As we limited
our search to five high-impact journals, it is possible that
we have overestimated the prevalence of delta inflation
because of omission of trials that more accurately pre-
dicted delta in other journals. This is unlikely because
high-impact journals are more likely to publish 'positive'
trials and those with larger sample sizes and larger
effects, and thus our analysis may have underestimated
the prevalence and impact of delta inflation. For the sake
of homogeneity, we limited our analysis to critical care
trials that utilized mortality as a primary endpoint, andAberegg et al. Critical Care 2010, 14:R77
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therefore our findings may not be generalizable to trials
in other specialties and those using other primary out-
comes. Nonetheless, the same pressures faced by critical
care investigators may be experienced by investigators in
other fields pursuing other outcomes who may likewise
be susceptible to delta inflation. Determination of the
prevalence of delta inflation in other arenas will require
specific study.
Conclusions
Delta inflation, a systematic overestimation in predic-
tions of treatment effect size during trial design, is com-
mon in randomized controlled trials of mortality in
critical care medicine. Reliable methods for predicting
delta during study design and better reporting of the basis
for these predictions are needed to minimize the risk of
trial failure from type II statistical errors and resulting
waste of research resources. Consideration should be
given to designing such trials with other clinically mean-
ingful primary endpoints. Critical care practitioners and
investigators must be aware that because of delta infla-
tion, negative results in randomized controlled trials do
not rule out efficacy of the therapies evaluated.
Key messages
• Most therapies for adult critical illness fail to dem-
onstrate efficacy in randomized controlled trials.
• In the design of randomized controlled trials, inves-
tigators must determine a realistic estimate of the
effect size (delta) of the therapy on an outcome of
interest such as mortality.
• In randomized controlled trials in critical care, pre-
dicted delta almost always exceeds the delta observed
in the trial data.
• This 'delta inflation' is a potential reason that most
such trials fail to demonstrate efficacy.
• Critical care practitioners and investigators must
bear in mind that 'absence of evidence is not evidence
of absence'.
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